medigraphic.com
SPANISH

Acta Médica Grupo Angeles

Órgano Oficial del Hospital Angeles Health System
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
    • Names and affiliations of the Editorial Board
  • Policies
  • About us
    • Data sharing policy
    • Stated aims and scope
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2011, Number 4

<< Back Next >>

Acta Med 2011; 9 (4)

Arterial hypertension secondary to Conn’s syndrome

Chirino RJ, Wiener CI, Cervantes VBM, Burgos ZÁ, Ruiz LJ, Alemán OG, Orozco OP
Full text How to cite this article

Language: Spanish
References: 14
Page: 221-224
PDF size: 245.51 Kb.


Key words:

Hyperaldosteronism, Conn’s syndrome, hyperkalaemia, laparoscopic adrenalectomy.

ABSTRACT

Primary hyperaldosteronism is one of the potentially curable forms of arterial hypertension. It is generally considered an uncommon disorder. However some experts believe that it may be the case of hypertension in 5% to 14% of the patients. In most of the cases, it is caused by a benign tumor of the adrenal gland and occurs between the age of 30 and 50 years. In these cases, the high blood pressure is secondary to the renal action of aldosterone. This causes an increase in salt and water reabsorption which leads to an increase in intravascular volume and secondarily to an increase in blood pressure. The treatment is the removal of the lesion with laparoscopic adrenalectomy.


REFERENCES

  1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.

  2. Viera A. Evaluation and management of the patient with difficult-to-control or resistant hypertension. Am Fam Physician 2009; 79: 863-869.

  3. Fardella C, Carvatal C, Mosso L. Primary hyperaldosteronism in the hypertensive disease. Curr Hypertens Reviews 2006; 2: 36-40.

  4. Harrison Principios de Medicina Interna 14º edición, McGraw-Hill Interamericana, Parte 9, Sección 5, 1549-1555.

  5. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Nor-mokalemic Primary Aldosteronism. A detectable cause of curable “Essential” hypertension. JAMA 1965; 193: 200-206.

  6. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050.

  7. Ram A. Conn syndrome Rev Infirm 2007; 129: 22.

  8. Sechi LA. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab 2009; 94(4): 1191-1197.

  9. McKenzie T, Lillegard J, Young W et al. Aldosteronomas-state of the art. Surg Clin N Am 2009; 89: 1241-1253.

  10. Vesin C. Diagnosis and post-operative evolution of patients operated for adrenal adenoma (Conn syndrome). A 12-years retrospective study. Arch Mal Coeur Vaiss 2007; 100(2): 121-125.

  11. Ziaja J. Rare normalization of blood pressure after unilateral adrenalectomy in 31 patients with Conn syndrome. Langenbecks Arch Surg 2007; 392(4): 431-435.

  12. Wang D, Terashi T. Laparoscopic adrenalectomy. Urol Clin N Am 2008; 35: 351-363.

  13. Foo R, O’Shaughnessy KM, Brown MJ. Hyperaldosteronism: recent concepts, diagnosis, and management. Postgrad Med J 2001; 77: 639-644.

  14. Young F. Minireview: Primary aldosteronism-Changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-2213.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med. 2011;9